Prevalence of Clinically Significant anti-HLA Antibodies in Renal Transplant Patients: Single-center Report from North India.
CDC crossmatch
DSA
HLA
renal transplant
single-antigen bead assay
Journal
Indian journal of nephrology
ISSN: 0971-4065
Titre abrégé: Indian J Nephrol
Pays: India
ID NLM: 8914356
Informations de publication
Date de publication:
Historique:
received:
19
10
2019
revised:
17
12
2019
accepted:
19
04
2020
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Solid organ transplantation is the preferred therapeutic modality of treatment in patients affected by terminal organ failures. Human leukocyte antigens (HLAs) plays an important role in graft survival. In many of the cases of rejection, antibodies are directed against HLA antigens expressed on the cells of the transplanted organ. Pre-transplant compatibility testing involves the use of different methodologies for the determination of anti-HLA antibodies. Luminex single-antigen bead (SAB) assay demonstrates higher sensitivity and specificity in detecting anti-HLA antibodies. The aim of this study was to determine the prevalence of anti-HLA antibodies in pre-transplant work up recipients, planned for renal transplant at a tertiary care center in India. 1640 patients visiting tertiary care hospital for pre-transplant compatibility testing were screened with complement-dependent micro-lymphocytotoxicity crossmatch (CDC-XM) and flow cytometric crossmatch (FC-XM). The patients positive for either or both screening tests were assayed with the Luminex SAB tests in order to establish defined antigen specificity of the alloantibodies and determining donor-specific antibody (DSA). The two most frequent antibodies identified in each A, B, C locus of HLA class I were -A*24:03 (43.9%), A*25:01 (36.6%), B*57:01 (40.3%), B*15:12 (37.1%), C*17:01 (61.9%), C*07:01 (52.4%) and in DR, DQ DP locus in HLA class II were DRB1*09:01(40.0%), DRB1*14:04(37.6%), DQA1*04:01/DQB1*03:03 (58.4%), DQA1*05:01/DQB1*03:01 (55.1%), DPA1*02:01/DPB1*17:01 (55.0%), DPA1*02:01/DPB1*05:01 (45.0%). This study has found the prevalence and specificity of anti-HLA antibodies in north India.
Identifiants
pubmed: 34376937
doi: 10.4103/ijn.IJN_353_19
pii: IJN-31-240
pmc: PMC8330640
doi:
Types de publication
Journal Article
Langues
eng
Pagination
240-244Informations de copyright
Copyright: © 2021 Indian Journal of Nephrology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
N Engl J Med. 1969 Apr 3;280(14):735-9
pubmed: 4886455
Am J Transplant. 2003 Dec;3(12):1488-500
pubmed: 14629279
Transplantation. 2008 Dec 27;86(12):1864-8
pubmed: 19104435
Transplant Rev (Orlando). 2013 Oct;27(4):108-11
pubmed: 23958238
Clin Transplant. 2000 Apr;14(2):167-73
pubmed: 10770424
Curr Opin Immunol. 2009 Oct;21(5):573-7
pubmed: 19765965
Pediatr Transplant. 2006 Feb;10(1):38-41
pubmed: 16499585
Hum Immunol. 2009 Aug;70(8):595-9
pubmed: 19527759
Transplantation. 2006 Dec 15;82(11):1524-8
pubmed: 17164726
Front Immunol. 2016 Dec 09;7:570
pubmed: 28018342
Indian J Hum Genet. 2010 Sep;16(3):108-10
pubmed: 21206696
Kidney Int. 2006 Oct;70(8):1474-81
pubmed: 16941026
Exp Clin Transplant. 2016 Nov;14(Suppl 3):53-55
pubmed: 27805512
Curr Opin Organ Transplant. 2010 Aug;15(4):462-6
pubmed: 20613523
Pediatr Nephrol. 2015 Apr;30(4):577-87
pubmed: 25062962